Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Nadjat Mounedji"'
Autor:
Timothy Price, Chiara Cremolini, Alfredo Falcone, Eric Van Cutsem, Julien Taieb, Jean-Marc Phelip, Jean-Baptiste Bachet, Lucjan Wyrwicz, Fabienne Portales, Ahmet Ozet, Irfan Cicin, Dan Atlan, Martin Becquart, Loick Vidot, Nadjat Mounedji
Publikováno v:
ESMO Open, Vol 5, Iss 3 (2020)
Externí odkaz:
https://doaj.org/article/f278b869784d4e0e9c442dc4a12a9eff
Autor:
Timothy Price, Chiara Cremolini, Alfredo Falcone, Eric Van Cutsem, Julien Taieb, Jean-Marc Phelip, Jean-Baptiste Bachet, Lucjan Wyrwicz, Fabienne Portales, Ahmet Ozet, Irfan Cicin, Dan Atlan, Martin Becquart, Loick Vidot, Nadjat Mounedji
Publikováno v:
ESMO Open, Vol 5, Iss 3 (2020)
Background In RECOURSE (, trifluridine/tipiracil significantly improved overall survival and progression-free survival (PFS) versus placebo in patients with pretreated metastatic colorectal cancer (mCRC). PRECONNECT was designed to further characteri
Externí odkaz:
https://doaj.org/article/d4363a641e6c4b95ba550f4e125c6b83
Autor:
Loick Vidot, Julien Taieb, Irfan Cicin, Ahmet Ozet, Martin Becquart, Fabienne Portales, Timothy J. Price, Chiara Cremolini, Dan Atlan, Jean-Marc Phelip, Jean-Baptiste Bachet, Nadjat Mounedji, Eric Van Cutsem, Alfredo Falcone, Lucjan Wyrwicz
Publikováno v:
Open
Open, 2020, 5 (3), pp.e000698. ⟨10.1136/esmoopen-2020-000698⟩
ESMO Open
Open, J. Wiltenburg, 2020, 5 (3), pp.e000698. ⟨10.1136/esmoopen-2020-000698⟩
ESMO Open, Vol 5, Iss 3 (2020)
Open, 2020, 5 (3), pp.e000698. ⟨10.1136/esmoopen-2020-000698⟩
ESMO Open
Open, J. Wiltenburg, 2020, 5 (3), pp.e000698. ⟨10.1136/esmoopen-2020-000698⟩
ESMO Open, Vol 5, Iss 3 (2020)
BACKGROUND: In RECOURSE (, trifluridine/tipiracil significantly improved overall survival and progression-free survival (PFS) versus placebo in patients with pretreated metastatic colorectal cancer (mCRC). PRECONNECT was designed to further character
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0aa2d1c5f07241302eb7c6faa34b0d96
https://lirias.kuleuven.be/handle/123456789/655767
https://lirias.kuleuven.be/handle/123456789/655767
Autor:
Gerald W. Prager, S. Moreno Vera, Dirk Arnold, Nadjat Mounedji, Julien Taieb, Antonio Quintela, Alexander Stein
Publikováno v:
Annals of Oncology
Background The optimal chemotherapeutic regimen for use beyond the second line for patients with metastatic colorectal cancer (mCRC) remains unclear. Materials and methods We systematically searched the Cochrane Database of Systematic Reviews, EMBASE
Autor:
Nadjat Mounedji, K. Cocks, Lucjan Wyrwicz, L. Vidot, Martin Becquart, Julien Taieb, X. Sun, Alfredo Falcone, Shanti Moreno, M. Greenwood
Publikováno v:
Value in Health. 22:S444-S445
Autor:
Martin Griesshammer, Giulia Benevolo, Jeannie Callum, Caroline Bensasson, Mahmudul Khan, Güray Saydam, Nadjat Mounedji, Timothy Devos, Alessandro M. Vannucchi, Francesca Palandri, Serdar Sivgin, Francesco Passamonti, Miklos Egyed
WOS: 000396341000050
PubMed ID: 27916398
Background In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK)1 and JAK2 inhibitor, was superior to best available therapy at controlling haematocrit and improving splenomegaly and sympt
PubMed ID: 27916398
Background In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK)1 and JAK2 inhibitor, was superior to best available therapy at controlling haematocrit and improving splenomegaly and sympt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::090c43d4820d3f977fc6b4e5a83a691b
https://hdl.handle.net/11454/32518
https://hdl.handle.net/11454/32518
Autor:
E. Francois, T. Andre, Timothy J. Price, Julien Edeline, Fabienne Portales, Julien Taieb, E. Van Cutsem, Alfredo Falcone, Nadjat Mounedji, S. Moreno Vera, J.F. Seitz, Martin Becquart, J.M. Phelip
Publikováno v:
Annals of Oncology. 29:v104-v105
Autor:
Christelle De La Fouchardiere, Nadjat Mounedji, Timothy J. Price, Julien Taieb, Loick Vidot, Christophe Borg, Jean-Baptiste Bachet, Marc Peeters, Lucjan Wyrwicz, Martin Becquart, Javier Sabater, Fortunato Ciardiello, Alfredo Falcone
Publikováno v:
Journal of Clinical Oncology. 37:638-638
638 Background: Pivotal RECOURSE trial assessed efficacy and safety of trifluridine/tipiracil (FTD/TPI) in mCRC patients (pts) without collecting QoL data. Here we describe a preliminary analysis of QoL in mCRC pts treated with FTD/TPI in the ongoing
Autor:
Julien Taieb, Martin Becquart, Fortunato Ciardiello, Alfredo Falcone, E. Van Cutsem, Sara Lonardi, J-B. Bachet, Nadjat Mounedji, Timothy J. Price, Lucjan Wyrwicz
Publikováno v:
Annals of Oncology. 29:viii155
Autor:
Julien Taieb, Lucjan Wyrwicz, Martin Becquart, Jean Francois Seitz, Nadjat Mounedji, Timothy J. Price, Shanti Moreno, Alfredo Falcone, Eric Van Cutsem
Publikováno v:
Journal of Clinical Oncology. 36:803-803
803 Background: Pivotal phase 3 RECOURSE trial evaluated efficacy and safety of trifluridine/tipiracil (FTD/TPI, also known TAS-102) in metastatic colorectal cancer (mCRC) without collecting quality of life (QoL) data (Mayer et al. N Engl J Med 2015;